e-learning
resources
Berlin 2008
Sunday, 05.10.2008
Animal models of pulmonary fibrosis: mechanisms and therapies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The PDE4 inhibitor roflumilast reduced bleomycin-induced pulmonary fibrotic and vascular remodeling in mice
in vivo
R. Benito, J. Cortijo, E. Donet, M. Mauricio, D. Ivars, E. Morcillo (Valencia, Spain)
Source:
Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies
Session:
Animal models of pulmonary fibrosis: mechanisms and therapies
Session type:
Thematic Poster Session
Number:
714
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Benito, J. Cortijo, E. Donet, M. Mauricio, D. Ivars, E. Morcillo (Valencia, Spain). The PDE4 inhibitor roflumilast reduced bleomycin-induced pulmonary fibrotic and vascular remodeling in mice
in vivo
. Eur Respir J 2008; 32: Suppl. 52, 714
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
The CDK4/6 inhibitor, palbociclib intensifies pulmonary inflammation in bleomycin-induced lung fibrosis
Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies
Year: 2020
Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019
Effect of NF-?B inhibitor IMD-1041 on BLM-induced pulmonary fibrosis in mice
Source: International Congress 2017 – Lung fibrosis: basic science
Year: 2017
Inhibition of the Arp2/3 complex inhibits lung myofibroblast differentiation in vitro and attenuates bleomycin-induced pulmonary fibrosis in mice
Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease
Year: 2019
Inhibition by roflumilast
vs
cilomilast of pulmonary leukocyte accumulation and TNFα release in a rat model of LPS-induced pulmonary neutrophilia
Source: Eur Respir J 2003; 22: Suppl. 45, 107s
Year: 2003
HSP47siRNA targeting to myofibroblasts attenuates bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside
Year: 2012
A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice
Source: Eur Respir J 2012; 40: 1475-1482
Year: 2012
Metformin attenuates bleomycin-induced pulmonary fibrosis in mice via IGF-1 suppression
Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias
Year: 2018
The influence of dexamethasone on the proliferation and apoptosis of pulmonary inflammatory cells in bleomycin-induced pulmonary fibrosis in rats
Source: Eur Respir J 2002; 20: Suppl. 38, 487s
Year: 2002
Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 461s
Year: 2005
Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension
Source: Eur Respir J 2003; 22: Suppl. 45, 20s
Year: 2003
Effect of fasudil on the bleomycin-induced pulmonary fibrosis and hypertension in mice
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms
Year: 2012
Effects of elastase inhibitor on the epithelial cell apoptosis in bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Year: 2008
HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
PD98059 attenuates the development of bleomycin-induced lung injury and fibrosis
Source: Annual Congress 2010 - Regulation of airway pharmacology
Year: 2010
Anti-fibrotic effect of telmisartan on bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies
Year: 2008
A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice
Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis
Year: 2010
Nintedanib inhibits contractile activity of lung myofibroblasts in a cellular model of scleroderma associated pulmonary fibrosis
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Year: 2018
Roflumilast N-oxide, a PDE4 inhibitor, curbs bleomycin-induced lung fibroblast activation
in vitro
Source: Annual Congress 2011 - Airway smooth muscle cells and fibroblasts: cell biology
Year: 2011
PAR-2 antagonist inhibits bleomycin-induced lung fibrosis.
Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept